Sign inJoin waitlistJoin the waitlist

Kate Lathrop

Program Director, Medical Oncology and Hematology Fellowship Program · University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of Medicine

Credentials: · · ·

History

Medical Oncology and Hematology Fellowship · University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of Medicine
Present
University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of Medicine
Present

University of Texas Health Science Center at San Antonio
2012–2014
University of Texas School of Medicine at San Antonio
2003–2007
Internal Medicine
University of Texas Health Science Center at San Antonio
2004–2007
Colorado College
2002

Research

Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer
Cancer Cell · 2021 · 190 citations
Sacituzumab Govitecan in patients with breast cancer brain metastases and recurrent glioblastoma: a phase 0 window-of-opportunity trial
Nature Communications · 2024 · 44 citations
Improving adherence to endocrine hormonal therapy among breast cancer patients: Study protocol for a randomized controlled trial
Contemporary Clinical Trials Communications · 2018 · 22 citations

Virginia Kaklamani
9 papers
Anand Karnad
3 papers
Melissa Accordino
3 papers
Pankil Shah
3 papers
RE
Richard Elledge
3 papers
AD
Aakash Desai
2 papers · 2 as a fellow
AM
Abdul Hai Mansoor
2 papers
Ali Khaki
2 papers
Amit Kulkarni
2 papers
Andrew Brenner
2 papers
AR
Atlantis Russ
2 papers · 2 as a fellow
Babar Bashir
2 papers

Clinical trials

Clinical Trial of Avasopasem in Patients With Metastatic Hormone Receptor Positive Breast Cancer With Progression on a CDK 4/6 Inhibitor and Hormonal Therapy
Principal investigator · Recruiting · Phase 1
The University of Texas Health Science Center at San Antonio
2025–2028
S-equol in Women With Triple Negative Breast Cancer
Principal investigator · Completed · Early phase 1
The University of Texas Health Science Center at San Antonio
2015–2020
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2023–2032
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Site PI · Recruiting · Phase 3
NRG Oncology
2023–2034